Afarak Group SE
ANOTHER FIN-FSA RELEASE IN THE MATTER AGAINST DR DANKO KONCAR
ANOTHER FIN-FSA RELEASE IN THE MATTER AGAINST DR DANKO KONCAR
10:15 London, 12:15 Helsinki, 6 November 2025 - Afarak Group SE ("Afarak" or "the Company") (LSE: AFRK, NASDAQ: AFAGR)
ANOTHER FIN-FSA RELEASE IN THE MATTER AGAINST DR DANKO KONCAR
Stock Exchange Release
On 6 November 2025, the Financial Supervisory Authority (FIN-FSA) has published attached information. Although this is not a company matter, Afarak was requested by Fin-FSA to inform its shareholders accordingly.
Helsinki, November 6, 2025
AFARAK GROUP SE
Board of Directors
For additional information, please contact:
Afarak Group SE
Guy Konsbruck, CEO, +356 2122 1566, guy.konsbruck@afarak.com
Financial reports and other investor information are available on the Company's website: www.afarak.com.
Afarak Group is a specialist alloy producer focused on delivering sustainable growth with a Speciality Alloys business in southern Europe and a FerroAlloys business in South Africa. The Company is listed on NASDAQ Helsinki (AFAGR) and the Main Market of the London Stock Exchange (AFRK).
Distribution:
NASDAQ Helsinki
London Stock Exchange
Main media
Attachments
Documents
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Digitalist Group Oyj6.11.2025 15:46:37 CET | Press release
Digitalist Group Oy - Managers' Transactions
Bavarian Nordic A/S6.11.2025 15:03:23 CET | Press release
Consortium consisting of Nordic Capital and Permira announces preliminary result of the takeover offer to shareholders of Bavarian Nordic and that the Offer is withdrawn and will not be completed
Bavarian Nordic A/S6.11.2025 15:03:23 CET | Pressemeddelelse
Konsortium bestående af Nordic Capital og Permira offentliggør det foreløbige resultat af overtagelsestilbuddet til aktionærerne i Bavarian Nordic og at Tilbuddet tilbagekaldes og ikke vil blive gennemført
Investeringsforeningen Wealth Invest6.11.2025 15:02:04 CET | Press release
Meddelelse om fejl NAV i Wealth Invest AlphaCura
Alvotech6.11.2025 15:00:00 CET | Press release
Alvotech and Advanz Pharma Receive Marketing Authorisations for Gobivaz®, a Biosimilar to Simponi® (golimumab), from the MHRA
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom